Author:
Wang Chuan-Xi,Lu Yan-Qin,Qi Peng,Chen Long-Hua,Han Jin-Xiang
Abstract
Abstract
Background
Hepatitis delta virus (HDV) ribozyme is an attractive molecular tool that can specifically recognize and catalyze the self-cleavage of the viral RNA phosphodiester backbone. However, a major obstacle in the medical application of the HDV ribozyme is the lack of specificity in the delivery of the ribozyme to defined target cells.
Results
The objective of this study was to determine whether retroviral vectors can deliver the HDV ribozyme into the target cells and to elucidate whether HDV ribozyme plays a role in hepatitis B virus (HBV) replication. In our study, the transduction of helper-free pseudotyped retrovirus, which showed a broad host range, in human hepatoma cells was performed under 2 conditions, that is, in the presence of polymerized human serum albumin (pHSA) and in the absence of pHSA. The transduction ability in the presence of pHSA was higher than in the absence of pHSA. Moreover, HBsAg and HBeAg levels after transductions with pHSA were significantly lower than those in the absence of pHSA, thus indicating that the recombinant retrovirus had HBV-specific cleavage activity and targeted HepG2215 cells.
Conclusions
These data suggest that this system provides a new approach for targeting hepatocytes and has a great potential in gene therapy for HBV infection.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Virology
Reference30 articles.
1. Kim WR: Epidemiology of hepatitis B in the United States. Hepatology 2009, 49: S28-34.
2. McMahon BJ: The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49: S45-55.
3. Tan A, Yeh SH, Liu CJ, Cheung C, Chen PJ: Viral hepatocarcinogenesis: from infection to cancer. Liver Int 2008, 28: 175-188.
4. Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, Tacklind J, Rutks I, Kane RL, Wilt TJ: Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med 2009, 150: 111-124.
5. Papadopoulos VP, Chrysagis DN, Protopapas AN, Goulis IG, Dimitriadis GT, Mimidis KP: Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study. Med Sci Monit 2009, 15: CR56-61.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献